Skip to main content
Caplight Logo









Zag Bio

Zag Bio

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://zagbio.com/

Last Round

Series A

Oct 28, 2025

Total Funding Raised

$80M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Zag Bio is a biotechnology company that develops thymus-targeted medicines for autoimmune diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

autoimmune diseasethymus targetingbifunctional antibodiesType 1 diabetesimmune toleranceimmunotherapycentral immune tolerancetherapeutic platformimmune reprogrammingimmune resetbiologicsdrug deliveryantigen delivery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Zag Bio Comparables

Compare Zag Bio with similar companies based on industry and business-model similarity.

Zag Bio comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Quell Therapeutics
78%
COUR Pharmaceuticals
77%
Parvus Therapeutics Inc.
77%

Zag Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 28, 2025

Key People

Founding team and executive leadership

Jason Cole

Chief Executive Officer and Board Member

Executive Team

Alison Conlon

Chief Operating Officer

Executive Team

Zag Bio Investors

Notable investors and investment history

Zag Bio investors
InvestorRounds
Boxer CapitalSeries A
Codon CapitalSeries A
GaingelsSeries A
Pear VCSeries A
AbbVie VenturesSeries A
Alexandria Venture InvestmentsSeries A
Sanofi VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors grew 73% MoM.

  • Jan 27, 2026

    Appointed Jan Hillson, M.D., with 20+ years of clinical development experience.

Zag Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Zag Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Zag Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range28
Year Founded2022
Last FundingOct 28, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?